Nuwiq

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
07-11-2022
Toote omadused Toote omadused (SPC)
07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
17-01-2018

Toimeaine:

simoctocog alfa

Saadav alates:

Octapharma AB

ATC kood:

B02BD02

INN (Rahvusvaheline Nimetus):

simoctocog alfa

Terapeutiline rühm:

Blood coagulation factors

Terapeutiline ala:

Hemophilia A

Näidustused:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Nuwiq can be used for all age groups.

Toote kokkuvõte:

Revision: 13

Volitamisolek:

Authorised

Loa andmise kuupäev:

2014-07-22

Infovoldik

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE USER
NUWIQ 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 1000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 1500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 2000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 2500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 4000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
simoctocog alfa (recombinant human coagulation factor VIII)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Nuwiq is and what it is used for
2.
What you need to know before you use Nuwiq
3.
How to use Nuwiq
4.
Possible side effects
5.
How to store Nuwiq
6.
Contents of the pack and other information
1.
WHAT NUWIQ IS AND WHAT IT IS USED FOR
Nuwiq contains the active substance human recombinant coagulation
factor VIII (simoctocog alfa).
Factor VIII is necessary for the blood to form clots and stop
bleeding. In patients with haemophilia A
(inborn factor VIII deficiency), factor VIII is missing or not working
properly.
Nuwiq replaces the missing factor VIII and is used for treatment and
prevention of bleeding in patients
with haemophilia A and can be used for all age groups.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE NUWIQ
DO NOT USE NUWIQ
•
if you are allergic to the active substance simoctocog alfa or any of
the other ingredients of
this medicine (listed in section 6).
If you are unsure about 
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Nuwiq 250 IU powder and solvent for solution for injection
Nuwiq 500 IU powder and solvent for solution for injection
Nuwiq 1000 IU powder and solvent for solution for injection
Nuwiq 1500 IU powder and solvent for solution for injection
Nuwiq 2000 IU powder and solvent for solution for injection
Nuwiq 2500 IU powder and solvent for solution for injection
Nuwiq 3000 IU powder and solvent for solution for injection
Nuwiq 4000 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Nuwiq 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 250 IU contains approximately 100 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 500 IU contains approximately 200 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 1000 IU contains approximately 400 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 1500 IU powder and solvent for solution for injection
Each vial contains nominally 1500 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 1500 IU contains approximately 600 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 2000 IU contains approximately 800 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 2500 IU powder and solvent for solution for injection
Ea
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 07-11-2022
Toote omadused Toote omadused bulgaaria 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 17-01-2018
Infovoldik Infovoldik hispaania 07-11-2022
Toote omadused Toote omadused hispaania 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 17-01-2018
Infovoldik Infovoldik tšehhi 07-11-2022
Toote omadused Toote omadused tšehhi 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 17-01-2018
Infovoldik Infovoldik taani 07-11-2022
Toote omadused Toote omadused taani 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande taani 17-01-2018
Infovoldik Infovoldik saksa 07-11-2022
Toote omadused Toote omadused saksa 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande saksa 17-01-2018
Infovoldik Infovoldik eesti 07-11-2022
Toote omadused Toote omadused eesti 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande eesti 17-01-2018
Infovoldik Infovoldik kreeka 07-11-2022
Toote omadused Toote omadused kreeka 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 17-01-2018
Infovoldik Infovoldik prantsuse 07-11-2022
Toote omadused Toote omadused prantsuse 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 17-01-2018
Infovoldik Infovoldik itaalia 07-11-2022
Toote omadused Toote omadused itaalia 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 17-01-2018
Infovoldik Infovoldik läti 07-11-2022
Toote omadused Toote omadused läti 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande läti 17-01-2018
Infovoldik Infovoldik leedu 07-11-2022
Toote omadused Toote omadused leedu 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande leedu 17-01-2018
Infovoldik Infovoldik ungari 07-11-2022
Toote omadused Toote omadused ungari 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande ungari 17-01-2018
Infovoldik Infovoldik malta 07-11-2022
Toote omadused Toote omadused malta 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande malta 17-01-2018
Infovoldik Infovoldik hollandi 07-11-2022
Toote omadused Toote omadused hollandi 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 17-01-2018
Infovoldik Infovoldik poola 07-11-2022
Toote omadused Toote omadused poola 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande poola 17-01-2018
Infovoldik Infovoldik portugali 07-11-2022
Toote omadused Toote omadused portugali 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande portugali 17-01-2018
Infovoldik Infovoldik rumeenia 07-11-2022
Toote omadused Toote omadused rumeenia 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 17-01-2018
Infovoldik Infovoldik slovaki 07-11-2022
Toote omadused Toote omadused slovaki 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 17-01-2018
Infovoldik Infovoldik sloveeni 07-11-2022
Toote omadused Toote omadused sloveeni 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 17-01-2018
Infovoldik Infovoldik soome 07-11-2022
Toote omadused Toote omadused soome 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande soome 17-01-2018
Infovoldik Infovoldik rootsi 07-11-2022
Toote omadused Toote omadused rootsi 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 17-01-2018
Infovoldik Infovoldik norra 07-11-2022
Toote omadused Toote omadused norra 07-11-2022
Infovoldik Infovoldik islandi 07-11-2022
Toote omadused Toote omadused islandi 07-11-2022
Infovoldik Infovoldik horvaadi 07-11-2022
Toote omadused Toote omadused horvaadi 07-11-2022
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 17-01-2018

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu